Genzyme Rejects Bid From Sanofi-Aventis

Vanessa — Mon, 30 Aug 2010 17:11:51 +0000

Are Biotechs Too Cheap?

This morning people woke up to shares of Genzyme Corp. (NASDAQ:GENZ) trading sharply higher in pre-market trading. On Sunday, Genzyme received an $18.5 billion offer from Sanofi-Aventis (NYSE:SNY) which comes to $69 per share.

The bid was rejected by the Genzyme Board despite their recent manufacturing issues. This decision could send a sign that many bio pharma stocks, including Genzyme are undervalued. We will probably see some increased volume and news flow early in the week from this sector. Especially with the mid and large cap names.

This M&A activity also bodes well for some of the unknown and under followed names on the OTCBB. Unlike most other sectors, excluding mining penny stocks, tiny microcap biotech and bio pharma stocks do get funding from larger companies from time to time.

For instance, giving a potential hot biotech penny stock $5 or $10 million dollars in R&D money is a small risk to take for a multi-billion dollar corporation looking for a new that could potentially become part of their pipeline.

While I can’t say for sure, it is probably safe to say that you will see some of the top penny stock newsletters writing about this trend in the next few weeks. Please keep in mind that the vast majority of biotech and biopharma stocks are very risky, and shouldn’t be owned by the feint of heart. However, this group has offered some investors some of the most massive gains.

So if you decide to buy one these biotech names of of a penny stock list, make sure you invest small. Also, when investing in a biotech always check their cash position and burn rate. These two numbers will tell you how much money the company has and how quickly they go through it.

Genzyme Rejects Bid From Sanofi-Aventis is news brought to you by Penny Stock Explosion. We provide up to date current information for hot penny stocks and penny stocks which are primed for explosion.

If you liked this Post, please share it!

Biotechnology Stock Genzymes’ (GENZ) Hostile Takeover When a stock like GENZ gets hot, volatility increases too....
Will Biotech Heat Up the Penny Stock World? Volatile and super liquid bio-pharma stocks like Rexhan Pharmaceuticals (AMEX:RNN)...
Potash Rejects All Cash Bid Traders who were long the Ag space woke up Tuesday...

Related posts brought to you by Yet Another Related Posts Plugin.

Hot Biotech Stocks like (AMEX:RPC) Primed to Rise

Vanessa — Wed, 28 Jul 2010 15:33:07 +0000

Radient Pharmaceuticals Corporation (AMEX:RPC)

We hope that everyone is enjoying their summer. We have not come out with a profile in a while because the markets have been turbulent. We have been seeing them bounce back lately and the Dow is back over 10,500. This is a crucial point. There is a lot of indication that big money is coming back into the markets investors are gaining confidence.

We have seen some small cap stocks have a substantial amount of money invested into them over the past few weeks. This is good news after we saw a huge drop off in the amount of money being invested in the small cap arena. Most penny stocks were either stagnant or drifting lower on little volume.

We have located an AMEX company that we feel is worth putting on our radar. RPC is a company that has had a lot of press so far this year. They company produces and markets cancer testing products. Back in early April RPC ran from .23 to 2.19 virtually over night. Millionaires were literally made in a day.

We have seen a drop off in price since then. It has found a home trading near the 1.00 level. When a company like RPC makes an 800% plus run like it did, we usually see two events happen that cause the share price to drift lower. (1) People take profits. If you just made that type of gain on your money you would be crazy not to take some of the winnings off of the table. (2) Shorts will come into the stock because they know that people will be taking profits and it will cause the price to decline. They take advantage of the declining price and even help it to go lower with the additional selling pressure that is applied when a stock is shorted.

This is why I love RPC. The stock was mostly accumulated at much higher levels. There was a period of 3 days back in April in which well over $100 million dollars worth of stock was bought. This is a huge amount of money for a small cap company like RPC.

Any type of news from the company could allow for a huge gap up. If you look at the chart you will see that most of the accumulation was done well above these levels. The break even price for investors is much higher than the current levels.

Make sure that you do your own research on RPC and consult a professional to see if it is a suitable investment for you. It has been known to be volatile in the past but at the same time it has been a huge home run for speculative investors.

We will keep you updated on RPC and periodically inform you of its progress. You can start your research at http://finance.yahoo.com/q?s=RPC and check out the company’s new website at http://www.radient-pharma.com/.

Hot Biotech Stocks like (AMEX:RPC) Primed to Rise is news brought to you by Penny Stock Explosion. We provide up to date current information for hot penny stocks and penny stocks which are primed for explosion.